Press Coverage

From Concept to Clearance: Why It's So Expensive to Develop New CV Drugs

Article about a JAMA study showing new cardiovascular drugs are developed at a cost more than 100-fold higher than the average refers to a paper co-authored by ISMP's senior scientist, Thomas Moore, that examined expenses associated with clinical trials and the factors that contribute to those costs.

For the full text, visit Cardiovascular Business online.

 

More News

An international medication safety call to action is aimed at preventing fatalities due to medication errors with concentrated potassium injection, inadvertent intraspinal injection of vincristine, and accidental daily instead of weekly dosing of methotrexate in patients with psoriasis or rheumatoid arthritis.